Purchase this article with an account.
A. P. Figueiredo, P. C. C. Ferreira, G. S. Lima, F. R. Lopes, A. Penella, A. Bogoni; Safety Use of Intracameral Moxifloxacin Solution in Cataract Surgery. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2904.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine whether moxifloxacin 0.5% ophthalmic solution can be safely injected intracamerally in patients after cataract surgery.
One hundred and ten eyes received an intracameral injection of moxifloxacin (0.1 mL 0.5% ophthalmic solution containing 500µg moxifloxacin) as the last step of phacoemulsification. All eyes were examinated one week before surgery, one day and 1-month after surgery regarding anterior chamber reaction, corneal endothelial cell density, corneal and retinal thickness.
The mean age was 63.3 years +/- 12.11 (SD) (range 47 to 81 years). All eyes had a postoperative best corrected visual acuity of 20/40 or better. All eyes had trace to +2 cells and flare anterior chamber reaction only on the first day after surgery. The mean endothelial cell count was 2517.22 cells/mm(2) preoperatively and 2401.41 cells/mm(2) postoperatively. The mean difference was 81 cells/mm(2), which not statistically significant (P = .629). The increase of 14.61µm postoperative pachymetry (P>.55) and 10.12 µm in retinal thickness (P>.63) 1 month after surgery was not statistically significant.
Intracameral moxifloxacin 0.5 mg/mL appeared to be nontoxic and a safe drug to be used after cataract surgery in order to prevent endophthalmitis.
This PDF is available to Subscribers Only